(OSE) – Business Wire
-
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
-
OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
-
OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors
-
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
-
OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
-
OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®
-
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
-
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
-
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
-
OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences
-
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
-
OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics
-
OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation
-
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplan
-
OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
-
OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
-
OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder’s Meeting
-
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
-
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
-
OSE Immunotherapeutics’ Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director
-
OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIG
-
OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab
-
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
-
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
-
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
-
OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology
-
OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies
-
OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
-
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
-
OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023
-
OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
-
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the Second Tranche of the Financing Granted by the European Investment Bank
-
OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual M
-
OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’
-
OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs
-
OSE Immunotherapeutics Announces Award for OSE-127's Upcoming Oral Presentation in Acute Lymphoblastic Leukemia
-
Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome
-
OSE Immunotherapeutics Updates on Tedopi®, a Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies
-
OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences
-
OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer
-
OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results
-
OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences
-
OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2
-
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
-
OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting
-
OSE Immunotherapeutics Announces Collaboration with Microsoft
-
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
-
OSE Immunotherapeutics SA: Four Poster Presentations at 2022 ASCO Annual Meeting
Back to OSE Stock Lookup
